Kinaplat 100mg Infusion

Kinaplat 100mg Infusion Description:

Kinaplat 100mg Infusion is an anti-cancer medication. It works by damaging the genetic material (DNA) of the cancer cells and stops their growth and multiplication.

Uses:

Kinaplat 100mg Infusion is used in the treatment of cancer of colon and rectum.

Side Effects:

Nausea, Fatigue, Anemia (low number of red blood cells), Vomiting, Diarrhoea, Decreased white blood cell count (neutrophils), Low blood platelets, Increased liver enzymes, Peripheral sensory neuropathy, Stomatitis (Inflammation of the mouth).

Dosage:

Your doctor or nurse will give you this medicine. Kindly do not self-administer.

FAQs

Is Kinaplat highly emetogenic
Kinaplat is highly emetogenic, can cause hair loss, temporary infertility, diarrhea, neuropathy, cold sensitivity. Kinaplat is not ototoxic

Is Kinaplat a vesicant
Kinaplat is a vesicant, chemotherapeutic drug. Kinaplat is not an alkylating agent it is a platinum containing antineoplastic agent

How is Kinaplat administered?
Kinaplat is administered as intravenous infusion or bolus injection.

Buy Kinaplat 100mg Infusion Online From India At Best Price

If you are looking to buy Oxaliplatin (100mg) (50 ml in 1 bottle) online at affordable prices, then Drugssquare.com is your one-stop solution. Drugssquare is a leading supplier, exporter and retailer of generic & branded prescription drugs in all around the world. From Cancer to Hepatitis, and from AIDS to Kidney Disease, the company delivers medicines for all kinds of complex diseases, with savings of up to 70% or more.

Order Online to Get Kinaplat 100mg Infusion in –

South East Asia – China, Cambodia, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Hong Kong, Japan, South Korea.

United Arab Emirates (UAE) – Saudi Arabia, Jordan.

North America – Venezuela, Suriname.

South America – Argentina, Chile, Colombia, Peru, Venezuela.

Russia CIS – Moldova, Uzbekistan, Kyrgyzstan.

African Countries – Nigeria, Kenya, Morocco, Libya, Zimbabwe.

Other Countries – Malaysia, Egypt, Australia, Italy and New Zealand.